Allscripts Announces Convertibility of its Outstanding 3.50 Percent Senior Debentures

llscripts announced today that its 3.50 percent Convertible Senior Debentures due 2024 (the “Debentures”) are now convertible at the option of the holders of the Debentures and will remain convertible during the fiscal quarter ending August 31, 2009. Any determinations regarding the convertibility o

CHICAGO (June 10, 2009) –

Allscripts announced today that its 3.50 percent Convertible Senior Debentures due 2024 (the “Debentures”) are now convertible at the option of the holders of the Debentures and will remain convertible during the fiscal quarter ending August 31, 2009. Any determinations regarding the convertibility of the Debentures during future periods will be made in accordance with the terms of the indenture under which the Debentures were issued (the “Indenture”).

The Debentures became convertible because the last reported sale price of Allscripts common stock for at least 20 consecutive trading days within the 30-trading-day period ending on May 29, 2009 was greater than 130 percent of the conversion price in effect on May 29, 2009. As a result, during the conversion period, holders of the Debentures may convert the Debentures into shares of common stock, subject to the terms of the Indenture. Pursuant to the terms of the Indenture, the Debentures are convertible at the conversion rate of 124.3781 shares per $1,000 principal amount of each Debenture. Allscripts has the right to satisfy the conversion with cash in lieu of shares of common stock in accordance with the terms of the Indenture.

Additionally, Allscripts announced today that, pursuant to the terms of the Indenture, holders of Debentures have the right to require Allscripts to repurchase their Debentures (the “Repurchase Right”) for cash in an amount equal to 100 percent of the principal amount of the Debentures ($1,000 per each $1,000 principal amount outstanding) plus accrued and unpaid interest and Liquidated Damages (as defined in the Indenture) to, but excluding, July 15, 2009. The Repurchase Right is subject to the terms and conditions described in the Notice of Right to Require Repurchase sent to Debenture holders and the Indenture. The Repurchase Right will expire at 5:00 p.m., Eastern Daylight Time, on July 15, 2009.

In order to surrender Debentures for purchase, a purchase notice must be delivered to Wilmington Trust FSB, as successor trustee and paying agent to LaSalle Bank N.A., or through The Depository Trust Company by 5:00 p.m., Eastern Daylight Time, on July 15, 2009. Holders may withdraw any Debentures previously surrendered for purchase at any time prior to 5:00 p.m., Eastern Daylight Time, on July 15, 2009 by delivering a notice of withdrawal to the paying agent at the address listed in the Notice of Right to Require Repurchase or through the Depository Trust Company. Debenture holders are urged to consult their tax advisor regarding the tax consequences of the foregoing.

About Allscripts

Allscripts (Nasdaq: MDRX) uses innovation technology to bring health to healthcare. More than 150,000 physicians, 700 hospitals and nearly 7,000 post-acute and homecare organizations utilize Allscripts to improve the health of their patients and their bottom line. The company’s award-winning solutions include electronic health records, electronic prescribing, revenue cycle management, practice management, document management, medication services, hospital care management, emergency department information systems and homecare automation. Allscripts is the brand name of Allscripts-Misys Healthcare Solutions, Inc. To learn more, visit www.allscripts.com.

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, actual results may vary materially from those anticipated by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry; possible regulation of the Company’s software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; the ability to recognize the benefits of the merger with Misys Healthcare Systems, LLC (“MHS”); the integration of MHS with the Company and the possible disruption of current plans and operations as a result thereof; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers; our ability to obtain, use or successfully integrate third-party licensed technology; breach of our security by third parties; and the risk factors detailed from time to time in our reports filed with the Securities and Exchange Commission, including our 2007 Annual Report on Form 10-K available through the Web site maintained by the Securities and Exchange Commission at www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Allscripts – 06/10/2009

CONTACT: Dan Michelson, Chief Marketing Officer, +1-312-506-1217,
dan.michelson@allscripts.com, or Todd Stein, Senior Manager/Public Relations,
+1-312-506-1216, todd.stein@allscripts.com, both of Allscripts
Web Site: http://www.allscripts.com
(MDRX)

CO: Allscripts; Allscripts-Misys Healthcare Solutions, Inc.

Source: Allscripts